Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis

作者：Hur H; Kim N K^*; Kim H G; Min B S; Lee K Y; Shin S J; Cheon J H; Choi S H

来源：British Journal of Cancer, 2012, 106(1): 53-60.

DOI：10.1038/bjc.2011.469

• unresectable colorectal liver metastasis
• neoadjuvant chemotherapy
• adenosine triphosphate-based chemotherapy response assay
• treatment response
• liver resection

BACKGROUND: This study aims to evaluate the effectiveness of adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided neoadjuvant chemotherapy for increasing resectability in patients with unresectable colorectal liver metastasis.
PATIENTS AND METHODS: Patients were randomised into two groups: Group A was treated by conventional chemotherapy regimen and Group B was treated by chemotherapy regimen according to the ATP-CRA. Three chemotherapeutic agents (5-fluorouracil, oxaliplatin and irinotecan) were tested by ATP-CRA and more sensitive agents were selected. Either FOLFOX or FOLFIRI was administered. Between Group A and B, treatment response and resectability were compared.
RESULTS: Between November 2008 and October 2010, a total 63 patients were randomised to Group A (N = 32) or Group B (N = 31). FOLFOX was more preferred in Group A than in Group B (26 out of 32 (81.3%) vs 20 out of 31 (64.5%)). Group B showed better treatment response than Group A (48.4% vs 21.9%, P = 0.027). The resectability of hepatic lesion was higher in Group B (35.5% vs 12.5%, P = 0.032). Mean duration from chemotherapy onset to the time of liver resection was 11 cycles (range 4-12) in Group A and 8 cycles (range 8-16) in Group B.
CONCLUSION: This study showed that tailored-chemotherapy based on ATP-CRA could improve the treatment response and resectability in initially unresectable colorectal liver metastasis. British Journal of Cancer (2012) 106, 53-60. doi:10.1038/bjc.2011.469 www.bjcancer.

• 出版日期2012-1-3